Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
about
The Impact of the Gut Microbiota on Drug Metabolism and Clinical OutcomeChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38Effects of methimazole on the elimination of irinotecan.Real-time imaging of intestinal bacterial β-glucuronidase activity by hydrolysis of a fluorescent probeA multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsHost-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics.Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.The human microbiome is a source of therapeutic drug targets.The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)Understanding and modulating mammalian-microbial communication for improved human health.Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsA randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.Pharmacogenetic pathway analysis of irinotecan.Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.The MDR1 C3435T polymorphism: effects on P-glycoprotein expression/function and clinical significanceRapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition.
P2860
Q28071938-2637293E-C5CF-4CF6-8CB3-ED01102A4B9AQ30318822-6A51A769-B720-447F-9BF8-7A686EFF65C7Q33183914-C3857E77-5075-4714-9CFC-7736A98FA1C2Q33647853-D4E3BA46-1DF5-4E98-85CF-B1550DD6139AQ33784710-3C1608C7-CDA0-41EC-9E69-3EDFEF109ADBQ33924277-08C63B88-D34B-42B9-8B01-0956211E0054Q34311685-652AAAC5-B7D2-45CD-87DF-F0E8BF04008CQ34391234-19551D78-7448-491A-906E-853A69DD3A06Q34726528-3A98622D-6CA3-46EF-90D3-3DE3DA61EFF1Q34996195-71F4F7E7-A166-46AE-AC48-BDCCD72E2074Q35026463-E75CEB8D-9A25-4388-A71E-260C4F7A333EQ35667216-51963D35-E22D-4816-A25C-C4B3296E7B69Q36615741-A8456481-1E04-4BB0-AE54-FDAD7CC22130Q37352037-087CEAEC-1114-4035-99B3-F3E4747414C8Q37381224-7D82FB87-EE80-4985-AEF3-635D27206B3DQ37731433-41452F81-A4A2-486E-A3BB-1441BC315FA0Q41818263-829EEA88-89F7-4857-A581-75D9A90332D1Q42180635-ADC6BFF7-E330-43C0-A291-B01BCAC67D2EQ47107453-7376333B-FFE6-4F1D-A468-C455D3B84CB2Q55408407-E9C81F38-AEDF-490A-A43D-037C6AE516F9
P2860
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@ast
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@en
type
label
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@ast
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@en
prefLabel
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@ast
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@en
P2093
P1476
Modulation of irinotecan-induc ...... h neomycin in cancer patients.
@en
P2093
A Sparreboom
C A Nierop
D F Kehrer
E J Ruijgrok
J van de Schraaf
M J de Jonge
P de Bruijn
P304
P407
P577
2001-05-01T00:00:00Z